Payment overview · 2025
General Payments
$2,148.63
110 reported records · 16 companies
Healthcare provider profile · identity verified
Ana Iris Rodriguez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1871599449
Verified facts
What the public records show
CMS Open Payments records show Ana Iris Rodriguez, MD received $2,148.63 in general payments during 2025 across 110 reported records.
ABBVIE INC. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 345 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $719.97 | 33.5% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $272.68 | 12.7% | 29 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $262.64 | 12.2% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $248.15 | 11.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $174.89 | 8.1% | 11 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $106.40 | 5.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $87.47 | 4.1% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.16 | 3.0% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $52.95 | 2.5% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $48.25 | 2.2% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $24.03 | 1.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.78 | 1.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.73 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.24 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.76 | 0.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.53 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,148.63 | 110 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $509.08 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $234.34 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $203.09 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $202.20 | 25 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $177.32 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $163.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $139.60 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.18 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.04 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $116.04 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $116.04 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $109.98 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $109.40 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $106.95 | 6 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $106.40 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $87.47 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $74.33 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $70.48 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $70.48 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $70.48 | 4 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $52.95 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $48.25 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $24.03 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 201 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 110 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 149 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 245 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 345 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
117 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
110 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
245 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
345 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
201 | 201 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 525 | 142 |
| Gabapentin | Gabapentin | 503 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 460 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 360 | 84 |
| Losartan Potassium | Losartan Potassium | 359 | 90 |
| Ozempic | Semaglutide | 345 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 81 |
| Lisinopril | Lisinopril | 322 | 79 |
| Montelukast Sodium | Montelukast Sodium | 296 | 78 |
| Metformin Hcl Er | Metformin Hcl | 295 | 81 |
| Mounjaro | Tirzepatide | 245 | 41 |
| Metformin Hcl | Metformin Hcl | 219 | 62 |
| Famotidine | Famotidine | 203 | 54 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 201 | 201 |
| Meloxicam | Meloxicam | 199 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 197 | 39 |
| Omeprazole | Omeprazole | 187 | 52 |
| Simvastatin | Simvastatin | 171 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 37 |
| Jardiance | Empagliflozin | 149 | 28 |
| Trazodone Hcl | Trazodone Hcl | 138 | 30 |
| Glimepiride | Glimepiride | 137 | 31 |
| Tramadol Hcl | Tramadol Hcl | 136 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 28 |
| Alprazolam | Alprazolam | 127 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 24 |
| Valsartan | Valsartan | 125 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 30 |
| Synthroid | Levothyroxine Sodium | 117 | 27 |
| Bupropion Xl | Bupropion Hcl | 111 | 27 |
| Pregabalin | Pregabalin | 111 | 31 |
| Farxiga | Dapagliflozin Propanediol | 110 | 21 |
| Celecoxib | Celecoxib | 106 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 25 |
| Sertraline Hcl | Sertraline Hcl | 92 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 91 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 28 |
| Irbesartan | Irbesartan | 86 | 17 |
| Clonazepam | Clonazepam | 81 | 17 |
| Estradiol | Estradiol | 77 | 24 |
| Ibandronate Sodium | Ibandronate Sodium | 77 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 27 |
| Solifenacin Succinate | Solifenacin Succinate | 72 | 17 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 70 | 70 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | 20 |
| Eliquis | Apixaban | 64 | suppressed |
| Carvedilol | Carvedilol | 63 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 61 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 16 |
| Azelastine Hcl | Azelastine Hcl | 59 | 32 |
| Trulicity | Dulaglutide | 58 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 18 |
| Alendronate Sodium | Alendronate Sodium | 54 | 15 |
| Eszopiclone | Eszopiclone | 54 | 11 |
| Furosemide | Furosemide | 54 | 19 |
| Fenofibrate | Fenofibrate,micronized | 53 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 34 |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Rybelsus | Semaglutide | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 14 |
| Topiramate | Topiramate | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 30 |
| Potassium Chloride | Potassium Chloride | 36 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 12 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Linzess | Linaclotide | 25 | 11 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Naproxen | Naproxen | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,148.63 · 110 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Da Vinci Surgical System, ELIQUIS, EVKEEZA, FARXIGA, GEMTESA, Heplisav-B, INSPIRE, JARDIANCE, KEVEYIS, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRINTELLIX, TZIELD, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error